Theseus Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview

Theseus Pharmaceuticals

01/11/2023 11:10

* Theseus Pharmaceuticals Inc  THRX.OQ   THRX.O  is expected
to show no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Theseus
Pharmaceuticals
Inc is for a loss of 36 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Theseus
Pharmaceuticals Inc is $7​, above​ its last closing price
of $2.30. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.35       -0.36      -0.34     Beat    5.6
 Mar. 31 2023  -0.43       -0.42      -0.34     Beat    18.9
 Dec. 31 2022  -0.44       -0.44      -0.35     Beat    21.1​
 Sep. 30 2022  -0.34       -0.34      -0.38     Missed  -11.8
 ​​Jun.        -0.29       -0.30      -0.30     Met     -1.4
 30 2022                                                
 Mar. 31 2022  -0.27       -0.26      -0.27     Missed  -1.9​
 Dec. 31 2021  -0.22       -0.22      -0.24     Missed  -6.7
 Sep. 30 2021  -0.24       -0.24      -5.16     Missed  -2,027
                                                        .8
 This summary was machine generated November 1 at 11:09 GMT.  All
figures in US dollars  unless otherwise stated